Oncimmune Holdings full year results and conference call

DirectorsTalk Interviews

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, states that it will be announcing its full year results for the year ended 31st May 2020 on Friday, 30 October 2020.

Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts at 11:30am GMT on the day of the results.

For conference call details please contact Alexander Davis of FTI Consulting at [email protected] or 020 3727 1000.

The management team will also host on Investor Meet Company a live presentation of the results on Friday, 30 October at 15:00 GMT.

• The online presentation will be open to all existing shareholders and potential new investors.

• Questions can be submitted before the event via your Investor Meet Company dashboard or at any time during the live presentation via the “Ask a Question” function. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.

• Investor feedback can also be submitted directly to management immediately following the event.

Access to Investor Meet Company is free and interested parties can register to attend the presentation via the following link: https://www.investormeetcompany.com/essensys-plc/register-investor

Attendees who have already registered on the Investor Meet Company platform to meet the Oncimmune Holdings will automatically receive an invitation to the presentation.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

India’s smart meter rollout builds a larger digital grid market

India’s smart meter rollout is moving into a larger execution phase, expanding demand across metering hardware, communications, software and digital grid services.

Verici Dx strengthens commercial case for kidney transplant risk test

Verici Dx has published analysis showing its PTRA kidney transplant risk test could generate more than $191 million in US healthcare savings over two years.

Serica holds firm on Pharos offer as rival bid gains ground

Serica Energy has declared its £145.7 million Pharos Energy offer final after a higher rival proposal gained the backing of the Pharos board.

Law Debenture: Why AI fears and a UK takeover wave are reshaping Laura Foll’s portfolio (video)

Law Debenture’s Laura Foll explains how the trust’s unusual structure has helped drive long-term outperformance.

GBG lowers FY27 revenue growth outlook amid Americas Identity attrition

GB Group now expects FY27 group revenue growth of 1–3% after higher-than-expected customer volume attrition in its Americas Identity business. Adjusted operating profit margin is expected to be approximately 21%.

    Search